enGene Therapeutics
ENGN· Manufacturing· Fiscal year ends in October
CEO pay in FY2025Stock -18.5% in FY2025
Ronald H.W. Cooper is the CEO of enGene Therapeutics and was paid $5.8M in FY2025 (Oct), down 32%.
Pay$100 in the stock at the end of FY24 → $81
Executives3
See all- 1Ronald H.W. CooperChief Executive Officer and PresidentFY2025
- 2Hussein SweitiChief Medical OfficerFY2025
- 3Ryan DawsChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allenGene Therapeutics paid its 3 named executives $11.1M in total in FY2025 (Oct). CEO Ronald H.W. Cooper was paid $5.8M of that.
| Name | |||
|---|---|---|---|
| Ronald H.W. CooperChief Executive Officer and President | Not disclosed | ||
| Hussein SweitiChief Medical Officer | Not disclosed | Not disclosed | |
| Ryan DawsChief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for enGene Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Gerald BrunkDirector · 2 yr on the boardIndependentResearch and Development—Paid as an executive
- Paul HastingsDirector · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Wouter JoustraDirector · 1 yr on the boardIndependent—Paid as an executive
- Dr. William GrossmanDirector · 0 yr on the boardIndependentResearch and Development (Chair)—Paid as an executive
- Michael HeffernanDirector · 0 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | May 8, 2026 | FY2025 |
| Annual report | 10-K | Dec 22, 2025 | FY2025 |
| Proxy statement | DEF 14A | May 9, 2025 | FY2024 |
| Annual report | 10-K | Dec 19, 2024 | FY2024 |
| Proxy statement | DEF 14A | Apr 18, 2024 | FY2023 |
| Annual report | 10-K | Jan 29, 2024 | FY2023 |
